NASDAQ:ANGO AngioDynamics (ANGO) Stock Price, News & Analysis → We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How) (From Paradigm Press) (Ad) Free ANGO Stock Alerts $6.25 -0.27 (-4.14%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$6.23▼$6.5350-Day Range$5.78▼$7.0352-Week Range$5.26▼$11.38Volume386,529 shsAverage Volume521,735 shsMarket Capitalization$250.38 millionP/E RatioN/ADividend YieldN/APrice Target$13.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get AngioDynamics alerts: Email Address AngioDynamics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.0% Upside$13.25 Price TargetShort InterestHealthy4.47% of Shares Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$67,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.57) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.40 out of 5 starsMedical Sector94th out of 905 stocksSurgical & Medical Instruments Industry16th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAngioDynamics has only been the subject of 2 research reports in the past 90 days.Read more about AngioDynamics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.47% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 16.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngioDynamics has received a 59.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ultrasound machines", "Clinical laser systems", and "Intravenous therapy equipment" products. See details.Environmental SustainabilityThe Environmental Impact score for AngioDynamics is -0.99. Previous Next 1.3 News and Social Media Coverage News SentimentAngioDynamics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for AngioDynamics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ANGO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $67,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AngioDynamics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AngioDynamics are expected to decrease in the coming year, from ($0.57) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AngioDynamics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY About AngioDynamics Stock (NASDAQ:ANGO)AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.Read More ANGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANGO Stock News HeadlinesMay 31, 2024 | americanbankingnews.comQ2 2025 EPS Estimates for AngioDynamics, Inc. (NASDAQ:ANGO) Decreased by Zacks ResearchMay 29, 2024 | bizjournals.comAngioDynamics CEO on what's next after outsourcing moveMay 22, 2024 | markets.businessinsider.comBuy Rating on AngioDynamics: Growth and Regulatory Approvals Underscore Positive OutlookMay 22, 2024 | finance.yahoo.comInvestors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three yearsMay 22, 2024 | markets.businessinsider.comANGO : AlphaVac F1885 Secures CE Mark For Non-Surgical Pulmonary Embolism Treatment In EuropeMay 21, 2024 | businesswire.comAngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ SystemMay 6, 2024 | finance.yahoo.comAngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific SessionsMay 6, 2024 | businesswire.comAngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific SessionsMay 3, 2024 | nasdaq.comAngioDynamics, Inc. Common Stock (ANGO)May 2, 2024 | finance.yahoo.comOppenheimer Predicts Over 100% Rally for These 2 Healthcare StocksApril 17, 2024 | finance.yahoo.comAngioDynamics, Inc. (ANGO) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | finance.yahoo.comInsider Spends US$67k Buying More Shares In AngioDynamicsApril 9, 2024 | seekingalpha.comA Leaner AngioDynamics Is A High-Risk Execution-Driven StoryApril 8, 2024 | finance.yahoo.comAngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call TranscriptApril 6, 2024 | finance.yahoo.comAngioDynamics Third Quarter 2024 Earnings: Misses ExpectationsApril 6, 2024 | seekingalpha.comAngioDynamics (ANGO) Q3 2024 Earnings Call TranscriptApril 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth OpportunitiesApril 6, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector PotentialApril 5, 2024 | msn.comAngioDynamics upgraded at Oppenheimer on pipeline progressApril 4, 2024 | finance.yahoo.comMedical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock SoarsApril 4, 2024 | marketwatch.comAngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 SystemApril 4, 2024 | markets.businessinsider.comANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024April 4, 2024 | marketwatch.comAngioDynamics Gets FDA Clearance For Pulmonary Embolism TreatmentApril 4, 2024 | marketwatch.comAngioDynamics Cut Fiscal-Year Revenue Outlook, Reflecting DivestmentsApril 4, 2024 | sfgate.comAngioDynamics: Fiscal Q3 Earnings SnapshotSee More Headlines Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/04/2024Today6/07/2024Next Earnings (Estimated)7/10/2024Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees815Year Founded1988Price Target and Rating Average Stock Price Target$13.25 High Stock Price Target$17.00 Low Stock Price Target$10.00 Potential Upside/Downside+112.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,440,000.00 Net Margins-60.21% Pretax Margin-61.53% Return on Equity-3.48% Return on Assets-2.68% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio1.62 Sales & Book Value Annual Sales$338.75 million Price / Sales0.74 Cash Flow$1.05 per share Price / Cash Flow5.93 Book Value$9.64 per share Price / Book0.65Miscellaneous Outstanding Shares40,060,000Free Float38,012,000Market Cap$250.38 million OptionableOptionable Beta0.68 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. James C. Clemmer (Age 60)CEO, President & Director Comp: $982.92kMr. Stephen A. Trowbridge (Age 50)Executive VP & CFO Comp: $528.02kMr. Chad T. Campbell (Age 53)Senior VP and GM of Global Vascular Access & Oncology Global Business Unit Comp: $416.51kMs. Laura Piccinini (Age 55)Senior VP & GM of International Comp: $444.31kMr. Saleem M. CheeksVice President of CommunicationsMr. Benjamin H. Davis (Age 60)Senior Vice President of Business Development Ms. Marna I. Bronfen-Moore (Age 57)Senior Vice President of Human Resources Mr. Warren G. Nighan (Age 55)Senior Vice President of Quality & Regulatory Affairs Comp: $622.11kMs. Kim L. Seabury (Age 57)Senior Vice President of Information Technology Mr. Juan Carlos SernaSenior Vice President of Scientific & Clinical AffairsMore ExecutivesKey CompetitorsSeaSpineNASDAQ:SPNECytosorbentsNASDAQ:CTSOSurmodicsNASDAQ:SRDXOrthofix MedicalNASDAQ:OFIXAccurayNASDAQ:ARAYView All CompetitorsInsiders & InstitutionsWestern Standard LLCBought 469,906 shares on 5/17/2024Ownership: 1.307%Jacobs Levy Equity Management Inc.Sold 156,261 shares on 5/16/2024Ownership: 1.713%Kennedy Capital Management LLCBought 154,002 shares on 5/16/2024Ownership: 0.475%Bayesian Capital Management LPBought 18,131 shares on 5/16/2024Ownership: 0.045%Price T Rowe Associates Inc. MDBought 2,821 shares on 5/15/2024Ownership: 0.084%View All Insider TransactionsView All Institutional Transactions ANGO Stock Analysis - Frequently Asked Questions Should I buy or sell AngioDynamics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANGO shares. View ANGO analyst ratings or view top-rated stocks. What is AngioDynamics' stock price target for 2024? 4 brokerages have issued 12-month price objectives for AngioDynamics' stock. Their ANGO share price targets range from $10.00 to $17.00. On average, they expect the company's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price. View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts. How have ANGO shares performed in 2024? AngioDynamics' stock was trading at $7.84 at the beginning of 2024. Since then, ANGO shares have decreased by 20.3% and is now trading at $6.25. View the best growth stocks for 2024 here. Are investors shorting AngioDynamics? AngioDynamics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,790,000 shares, a decline of 16.7% from the April 30th total of 2,150,000 shares. Based on an average daily volume of 517,200 shares, the short-interest ratio is presently 3.5 days. View AngioDynamics' Short Interest. When is AngioDynamics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our ANGO earnings forecast. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Thursday, April, 4th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.02. AngioDynamics had a negative trailing twelve-month return on equity of 3.48% and a negative net margin of 60.21%. What ETF holds AngioDynamics' stock? Invesco Nasdaq Future Gen 200 ETF holds 7,543 shares of ANGO stock, representing 0.61% of its portfolio. What guidance has AngioDynamics issued on next quarter's earnings? AngioDynamics updated its FY 2024 earnings guidance on Thursday, April, 4th. The company provided EPS guidance of -0.580--0.540 for the period, compared to the consensus estimate of -0.430. The company issued revenue guidance of $270.0 million-$275.0 million, compared to the consensus revenue estimate of $312.1 million. What is James C. Clemmer's approval rating as AngioDynamics' CEO? 34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX). Who are AngioDynamics' major shareholders? AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.57%), Acadian Asset Management LLC (2.53%), Assenagon Asset Management S.A. (2.03%), Jacobs Levy Equity Management Inc. (1.71%), Western Standard LLC (1.31%) and Kennedy Capital Management LLC (0.47%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does AngioDynamics have any subsidiaries? The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.Read More This page (NASDAQ:ANGO) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AngioDynamics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.